keyword
MENU ▼
Read by QxMD icon Read
search

EULAR recommendations

keyword
https://www.readbyqxmd.com/read/28339992/rheumatoid-arthritis-specific-cardiovascular-risk-scores-are-not-superior-to-general-risk-scores-a-validation-analysis-of-patients-from-seven-countries
#1
Cynthia S Crowson, Sherine E Gabriel, Anne Grete Semb, Piet L C M van Riel, George Karpouzas, Patrick H Dessein, Carol Hitchon, Virginia Pascual-Ramos, George D Kitas
Objectives.: Cardiovascular disease (CVD) risk calculators developed for the general population do not accurately predict CVD events in patients with RA. We sought to externally validate risk calculators recommended for use in patients with RA including the EULAR 1.5 multiplier, the Expanded Cardiovascular Risk Prediction Score for RA (ERS-RA) and QRISK2. Methods.: Seven RA cohorts from UK, Norway, Netherlands, USA, South Africa, Canada and Mexico were combined...
March 8, 2017: Rheumatology
https://www.readbyqxmd.com/read/28298374/safety-of-synthetic-and-biological-dmards-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-management-of-rheumatoid-arthritis
#2
Sofia Ramiro, Alexandre Sepriano, Katerina Chatzidionysiou, Jackie L Nam, Josef S Smolen, Désirée van der Heijde, Maxime Dougados, Ronald van Vollenhoven, Johannes W Bijlsma, Gerd R Burmester, Marieke Scholte-Voshaar, Louise Falzon, Robert B M Landewé
OBJECTIVES: To assess the safety of synthetic (s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA) to inform the European League Against Rheumatism recommendations for the management of RA. METHODS: Systematic literature review (SLR) of observational studies comparing any DMARD with another intervention for the management of patients with RA. All safety outcomes were included. A comparator group was required for the study to be included...
March 15, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28283512/efficacy-of-biological-disease-modifying-antirheumatic-drugs-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-the-management-of-rheumatoid-arthritis
#3
Jackie L Nam, Kaoru Takase-Minegishi, Sofia Ramiro, Katerina Chatzidionysiou, Josef S Smolen, Désirée van der Heijde, Johannes W Bijlsma, Gerd R Burmester, Maxime Dougados, Marieke Scholte-Voshaar, Ronald van Vollenhoven, Robert Landewé
OBJECTIVES: To update the evidence for the efficacy of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) to inform European League Against Rheumatism (EULAR) Task Force treatment recommendations. METHODS: MEDLINE, EMBASE and Cochrane databases were searched for phase III or IV (or phase II, if these studies were lacking) randomised controlled trials (RCTs) published between January 2013 and February 2016. Abstracts from the American College of Rheumatology and EULAR conferences were obtained...
March 10, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28277255/recommendations-for-the-use-of-ultrasound-and-magnetic-resonance-in-patients-with-spondyloarthritis-including-psoriatic-arthritis-and-patients-with-juvenile-idiopathic-arthritis
#4
Jacqueline Uson, Estibaliz Loza, Ingrid Möller, Carlos Acebes, Jose Luis Andreu, Enrique Batlle, Ángel Bueno, Paz Collado, Juan Manuel Fernández-Gallardo, Carlos González, Mercedes Jiménez Palop, María Pilar Lisbona, Pilar Macarrón, Joan Maymó, Jose Antonio Narváez, Victoria Navarro-Compán, Jesús Sanz, M Piedad Rosario, Esther Vicente, Esperanza Naredo
OBJECTIVE: To develop evidence-based recommendations on the use of ultrasound (US) and magnetic resonance imaging in patients with spondyloarthritis, including psoriatic arthritis, and juvenile idiopathic arthritis. METHODS: Recommendations were generated following a nominal group technique. A panel of experts (15 rheumatologists and 3 radiologists) was established in the first panel meeting to define the scope and purpose of the consensus document, as well as chapters, potential recommendations and systematic literature reviews (we used and updated those from previous EULAR documents)...
October 27, 2016: Reumatología Clinica
https://www.readbyqxmd.com/read/28264816/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-and-biological-disease-modifying-antirheumatic-drugs-2016-update
#5
Josef S Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, Jackie Nam, Sofia Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Chris D Buckley, Frank Buttgereit, Vivian Bykerk, Mario Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk-Hustings, Paul Emery, Axel Finckh, Cem Gabay, Juan Gomez-Reino, Laure Gossec, Jacques-Eric Gottenberg, Johanna M W Hazes, Tom Huizinga, Meghna Jani, Dmitry Karateev, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain McInnes, Eduardo Mysler, Peter Nash, Karel Pavelka, Gyula Poór, Christophe Richez, Piet van Riel, Andrea Rubbert-Roth, Kenneth Saag, Jose da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib)...
March 6, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28223263/apps-for-people-with-rheumatoid-arthritis-to-monitor-their-disease-activity-a-review-of-apps-for-best-practice-and-quality
#6
Rebecca Grainger, Hermaleigh Townsley, Bonnie White, Tobias Langlotz, William J Taylor
BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory arthritis requiring long-term treatment with regular monitoring by a rheumatologist to achieve good health outcomes. Since people with RA may wish to monitor their own disease activity with a smartphone app, it is important to understand the functions and quality of apps for this purpose. OBJECTIVE: The aim of our study was to assess the features and quality of apps to assist people to monitor their RA disease activity by (1) summarizing the available apps, particularly the instruments used for measurement of RA disease activity; (2) comparing the app features with American College of Rheumatology and European League against Rheumatism (ACR and EULAR) guidelines for monitoring of RA disease activity; and (3) rating app quality with the Mobile App Rating Scale (MARS)...
February 21, 2017: JMIR MHealth and UHealth
https://www.readbyqxmd.com/read/28176966/efficacy-and-safety-of-non-pharmacological-and-non-biological-pharmacological-treatment-a-systematic-literature-review-informing-the-2016-update-of-the-asas-eular-recommendations-for-the-management-of-axial-spondyloarthritis
#7
COMMENT
Andrea Regel, Alexandre Sepriano, Xenofon Baraliakos, Désirée van der Heijde, Jürgen Braun, Robert Landewé, Filip Van den Bosch, Louise Falzon, Sofia Ramiro
To assess the efficacy and safety of non-biological therapies in patients with axial spondyloarthritis (axSpA) to inform the update of the Assessment of SpondyloArthritis international Society (ASAS)/European League Against Rheumatism (EULAR) recommendations for the management of axSpA. A systematic literature review (2009-2016) of all non-pharmacological treatments, non-biological drugs (except targeted synthetic disease-modifying antirheumatic drugs (DMARDs)) and surgical therapies was performed. Randomised controlled trials (RCTs) and clinical controlled trials were assessed for efficacy and safety, while observational studies with a comparator were assessed for safety...
2017: RMD Open
https://www.readbyqxmd.com/read/28176964/efficacy-and-safety-of-biological-and-targeted-synthetic-dmards-a-systematic-literature-review-informing-the-2016-update-of-the-asas-eular-recommendations-for-the-management-of-axial-spondyloarthritis
#8
Alexandre Sepriano, Andrea Regel, Désirée van der Heijde, Jürgen Braun, Xenofon Baraliakos, Robert Landewé, Filip Van den Bosch, Louise Falzon, Sofia Ramiro
OBJECTIVES: To update the evidence for the efficacy and safety of (b)biological and (ts)targeted-synthetic disease-modifying anti-rheumatic drugs (DMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2016 update of the Assessment of SpondyloArthritis international Society/European League Against Rheumatism (ASAS/EULAR) recommendations for the management of axSpA. METHODS: Systematic literature review (2009-2016) for randomised controlled trials (RCT), including long-term extensions, strategy trials and observational studies (the latter was only for safety assessment and a comparator was required)...
2017: RMD Open
https://www.readbyqxmd.com/read/28161110/-discontinuation-or-tapering-strategies-of-biologics-in-rheumatoid-arthritis-in-remission
#9
A Mallick, B Fautrel, F Sagez, C Sordet, R-M Javier, H Petit, E Chatelus, N Rahal, J-E Gottenberg, J Sibilia
The arrival of new drugs and new therapeutic strategies allowed to reach sustained remission in an increasing number of patients with rheumatoid arthritis. The study of biologic disease-modifying anti-rheumatic drugs (bDMARDs) adaptation strategies is a need to optimize the benefit/risk balance and cost/effectiveness ratio of these molecules. Current recommendations such as EULAR 2016 propose tapering bDMARDs, especially when combined with a csDMARD, when the patient is in remission after stopping persistent glucocorticoids...
February 1, 2017: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/28155923/diagnosis-prognosis-and-classification-of-early-arthritis-results-of-a-systematic-review-informing-the-2016-update-of-the-eular-recommendations-for-the-management-of-early-arthritis
#10
COMMENT
Charlotte Hua, Claire I Daien, Bernard Combe, Robert Landewe
OBJECTIVE: To update the evidence pertaining to the diagnosis, prognosis and classification of patients with early arthritis (EA), and to inform the 2016 European League Against Rheumatism (EULAR) recommendations for the management of patients with EA. METHODS: MEDLINE, EMBASE and Cochrane databases were searched up to October 2015. The first part of the systematic literature review (SLR) involved a search for studies investigating the recognition and referral of EA...
2017: RMD Open
https://www.readbyqxmd.com/read/28151539/non-pharmacological-and-pharmacological-interventions-in-patients-with-early-arthritis-a-systematic-literature-review-informing-the-2016-update-of-eular-recommendations-for-the-management-of-early-arthritis
#11
Claire Immediato Daien, Charlotte Hua, Bernard Combe, Robert Landewe
OBJECTIVE: To perform a systematic literature review (SLR) on pharmacological and non-pharmacological treatments, in order to inform the European League Against Rheumatism (EULAR) recommendations for the management of early arthritis (EA). METHODS: The expert committee defined research questions concerning non-pharmacological interventions, patient information and education, non-steroidal anti-inflammatory drug, glucocorticoid (GC) and disease-modifying antirheumatic drugs (DMARDs) use, as well as on disease monitoring...
2017: RMD Open
https://www.readbyqxmd.com/read/28150104/assessment-of-six-cardiovascular-risk-calculators-in-mexican-mestizo-patients-with-rheumatoid-arthritis-according-to-the-eular-2015-2016-recommendations-for-cardiovascular-risk-management
#12
Dionicio A Galarza-Delgado, Jose R Azpiri-Lopez, Iris J Colunga-Pedraza, Jesus A Cardenas-de la Garza, Raymundo Vera-Pineda, Griselda Serna-Peña, Rosa I Arvizu-Rivera, Adrian Martinez-Moreno, Martin Wah-Suarez, Mario A Garza Elizondo
Variability of the 10-year cardiovascular (CV) risk predicted by the Framingham Risk Score (FRS) using lipids, FRS using body mass index (BMI), Reynolds Risk Score (RRS), QRISK2, Extended Risk Score-Rheumatoid Arthritis (ERS-RA), and algorithm developed by the American College of Cardiology and the American Heart Association in 2013 (ACC/AHA 2013) according to the European League Against Rheumatism (EULAR) 2015/2016 update of its evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis (RA) has not been evaluated in Mexican mestizo patients...
February 1, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28123778/factors-influencing-the-use-of-tocilizumab-as-monotherapy-in-patients-with-rheumatoid-arthritis-in-a-real-life-setting-results-at-1%C3%A2-year-of-the-act-solo-study
#13
René-Marc Flipo, Jean-Francis Maillefert, Pascal Chazerain, Isabelle Idier, Mathieu Coudert, Jacques Tebib
INTRODUCTION: Using a biologic disease-modifying antirheumatic drug (bDMARD) as monotherapy in clinical practice for patients with rheumatoid arthritis (RA) is common and recognised by health authorities although current guidelines recommend to combine them with conventional synthetic (cs)DMARDs. This study mainly aimed to search for real-life factors influencing the use of tocilizumab as MONO or in combination (COMBO). METHODS: In this non-interventional, prospective, national, multicentre study, data were collected every 3 months over a 12-month period in RA patients starting tocilizumab...
2017: RMD Open
https://www.readbyqxmd.com/read/28120818/pregnancy-and-menopause-in-patients-with-systemic-lupus-erythematosus-and-or-antiphospholipid-syndrome-practical-guide-from-eular
#14
Roberta Vagelli, Chiara Tani, Marta Mosca
Over the last few decades, in reproductive medicine have allowed an improvement in the management and outcome of pregnancy in connective tissue diseases (CTD), such as Systemic progress Lupus Erythematosus and Antiphospholipid Syndrome; however, pregnancy and other related issues represent a crucial moment for patients and their family and some unmet needs are still present. In routine clinical practise, health professionals involved in the care of SLE and/or APS patients need to consider many aspects of the reproductive life of patients, involving not only pregnancy and family planning but also fertility, contraception, cancer surveillance and menopause...
January 25, 2017: Polskie Archiwum Medycyny Wewnętrznej
https://www.readbyqxmd.com/read/28089973/malignancies-in-patients-with-anti-rna-polymerase-iii-antibodies-and-systemic-sclerosis-analysis-of-the-eular-scleroderma-trials-and-research-cohort-and-possible-recommendations-for-screening
#15
Maria-Grazia Lazzaroni, Ilaria Cavazzana, Enrico Colombo, Rucsandra Dobrota, Jasmin Hernandez, Roger Hesselstrand, Cecilia Varju, Gabriella Nagy, Vanessa Smith, Paola Caramaschi, Valeria Riccieri, Eric Hachulla, Alexandra Balbir-Gurman, Emmanuel Chatelus, Katarzyna Romanowska-Próchnicka, Ana Carolina Araújo, Oliver Distler, Yannick Allanore, Paolo Airò
OBJECTIVE: To analyze the characteristics of anti-RNA polymerase III antibodies (anti-RNAP3)- positive patients with systemic sclerosis (SSc) in the European League Against Rheumatism Scleroderma Trials and Research group (EUSTAR) registry with a focus on the risk of cancer and the characteristics of malignancies, and the aim to provide guidelines about potential cancer screening in these patients. METHODS: (1) Analysis of the EUSTAR database: 4986 patients with information on their anti-RNAP3 status were included...
January 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28088339/evidence-based-management-of-systemic-sclerosis-navigating-recommendations-and-guidelines
#16
REVIEW
Russell Edward Pellar, Janet Elizabeth Pope
OBJECTIVES: Systemic sclerosis (SSc) is a rare heterogeneous connective tissue disease. Recommendations addressing the major issues in the management of SSc including screening and treatment of organ complications are needed. METHODS: The updated European League Against Rheumatism/European Scleroderma Trial and Research (EULAR/EUSTAR) and the British Society of Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) guidelines were compared and contrasted...
December 9, 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28087505/2016-update-of-the-asas-eular-management-recommendations-for-axial-spondyloarthritis
#17
Désirée van der Heijde, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados, Floris van Gaalen, Pál Géher, Irene van der Horst-Bruinsma, Robert D Inman, Merryn Jongkees, Uta Kiltz, Tore K Kvien, Pedro M Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compàn, Salih Ozgocmen, Fernando M Pimentel-Santos, John Reveille, Martin Rudwaleit, Jochen Sieper, Percival Sampaio-Barros, Dieter Wiek, Jürgen Braun
To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009...
January 13, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28077693/new-grappa-and-eular-recommendations-for-the-management-of-psoriatic-arthritis-process-and-challenges-faced
#18
EDITORIAL
Laura C Coates, Laure Gossec, Sofia Ramiro, Philip Mease, Désirée van der Heijde, Josef S Smolen, Christopher Ritchlin, Arthur Kavanaugh
No abstract text is available yet for this article.
January 11, 2017: Rheumatology
https://www.readbyqxmd.com/read/28053333/connective-tissue-disease-reflections-on-the-eular-recommendations-for-the-treatment-of-systemic-sclerosis
#19
Janet E Pope
No abstract text is available yet for this article.
March 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28034828/evidenced-based-guidelines-on-the-treatment-of-fibromyalgia-patients-are-they-consistent-and-if-not-why-not-have-effective-psychological-treatments-been-overlooked
#20
Kati Thieme, Marc Mathys, Dennis C Turk
We compared the recommendations and methodology of several recent evidence-based guidelines for the management of patients with fibromyalgia published by professional organizations: 1) American Pain Society (APS; 2005), 2) Association of the Scientific Medical Societies in Germany (AWMF; 2012), 3) Canadian Pain Society (CPS; 2013; also used in the United Kingdom), and 4) European League Against Rheumatism (EULAR; 2016). Each guideline used systematic reviews and meta-analyses as highest level of evidence; APS, CPS, and AWMF also included individual randomized clinical trials...
December 27, 2016: Journal of Pain: Official Journal of the American Pain Society
keyword
keyword
108134
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"